Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note First and only FDA-approved drug for hallucinations and delusions associated with PDP (approved April 2016; launched May 2016).
Trofinetide (DAYBUE)
Approved · Active
Aliases DAYBU, DAYBUE STIX
Target IGF-1
Partnerships Neuren Pharmaceuticals: $10M upfront (2018, North America) + up to $455M milestones, tiered double-digit royalties; expanded Jul 2023: $100M upfront, up to $426.3M milestones (trofinetide ex-NA), mid-teens to low-twenties royalties ex-NA; Neuren entitled to one-third of $146.5M PRV sale proceeds.
Indications
Rett syndrome(Approved)
Status note First and only approved Rett syndrome therapy: US Mar 2023, Canada Oct 2024, Israel Dec 2025; DAYBUE STIX approved Dec 2025 (limited availability Q1 2026, broader launch Q2 2026). CHMP adopted positive opinion Jun 2026 (re-examination) recommending EU marketing authorization for DAYBU; EC decision pending.
Remlifanserin
Phase 2/3 · Active
Target serotonergic system
Indications
Alzheimer's disease psychosis (ADP)(Phase 2/3)
Lewy Body Dementia psychosis (LBDP)(Phase 2)
Catalysts
— September-October 2026
Status note Most advanced current product candidate per this filing. RADIANT ADP program: Phase 2 portion enrollment complete, Phase 3 portion screening/enrolling (judgment call PHASE_2_3); additional Phase 2 study in LBDP initiated Sep 2025. FDA Fast Track granted Jul 2026 for ADP.
ACP-211
Phase 2 · Active
Indications
Major depressive disorder (MDD)(Phase 2)
Status note Phase 2 study in MDD initiated Q4 2025. 10-Q states no topline timing.
ACP-711
Phase 1 · Active
Target GABAA-a3
Partnerships Saniona A/S: $28M upfront; up to $582M milestones ($147M development/commercial for first and second indications + $435M sales thresholds); tiered royalties mid-single digits to low double digits.
Indications
Essential tremor(Phase 1)
Catalysts
— 2027
Status note Highly selective GABAA-a3 positive allosteric modulator; Phase 1 complete; Phase 2 in essential tremor expected to begin in 2027.
ACP-271
Phase 1 · Active
Target GPR88
Status note GPR88 agonist; first-in-human study in healthy volunteers initiated Q1 2026. 10-Q states no indication.
NNZ-2591
Stage not disclosed · Active
Aliases ercanetide
Partnerships Neuren Pharmaceuticals: global rights under Jul 2023 expanded agreement; up to $831.3M NNZ-2591 development/sales milestones; royalties identical to trofinetide tiers.
Indications
Rett syndrome(Stage not disclosed)
Fragile X syndrome(Stage not disclosed)
Status note Neuren development candidate; 10-Q states licensed global rights in Rett syndrome and Fragile X syndrome but no clinical stage.
SYNGAP1 program
Stage not disclosed · ActiveModality: RNA-based medicine
Target SYNGAP1
Partnerships Stoke Therapeutics: $60M upfront; up to $245M milestones; 50/50 worldwide cost/profit share on the SYNGAP1 program.
Indications
SYNGAP1-related neurodevelopmental disease(Stage not disclosed)
Status note RNA-based medicines collaboration for severe and rare genetic neurodevelopmental CNS diseases; 10-Q states no stage.
Status note Discontinued May 2025; licenses to the MECP2 program terminating and activities winding down.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.